Aberrant expression of KPNA2 is associated with a poor prognosis and contributes to OCT4 nuclear transportation in bladder cancer.
Recent studies show that Karyopherin alpha 2 (KPNA2) is up-regulated in quite a number of cancers and associated with poor prognosis. Here, we found that expression levels of KPNA2 and OCT4 are up-regulated in bladder cancer tissues and significantly associated with primary tumor stage and bladder cancer patients' poorer prognosis. Our data also showed decreased cell proliferation and migration rates of bladder cancer cell lines when the expression of KPNA2 and OCT4 was silenced. Meanwhile, cell apoptosis rate was increased. Furthermore, Co-IP and immunofluorescence assay showed the KPNA2 interacts with OCT4 and inhibits OCT4 nuclear transportation when KPNA2 was silenced. Thus, we confirmed that up-regulated KPNA2 and OCT4 expression is a common feature of bladder cancer that is correlated with increased aggressive tumor behavior. Also, we propose that KPNA2 regulates the process of OCT4 nuclear transportation in bladder cancer.
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Jingcheng
J
Zhou
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Daoquan
D
Dong
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Ran
R
Cheng
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Yan
Y
Wang
Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China.
Shuqi
S
Jiang
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Yuhong
Y
Zhu
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Longlong
L
Fan
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Xiangming
X
Mao
Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China.
Yaoting
Y
Gui
Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China.
Zesong
Z
Li
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.|Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China.|Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, Guangdong 518112, China.
Xianxin
X
Li
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
Bentao
B
Shi
D021581:Active Transport, Cell Nucleus; D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000235:genetics; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D020868:Gene Silencing; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D050814:Octamer Transcription Factor-3 / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D034741:RNA, Small Interfering / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D028901:alpha Karyopherins / Q000235:genetics*
D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; D034741:RNA, Small Interfering; D028901:alpha Karyopherins; C087978:karyopherin alpha 2; D053148:Caspase 3
KPNA2; OCT4; bladder cancer; nucleo-cytoplasmic transport; prognostic